Vascular disease antibody new drug corporations Ingenia Therapeutics was listed on the KOSDAQ market on the 18th. Following a retina disease treatment that achieved global technology transfer, it plans to expand growth momentum through subsequent new drug development and additional technology transfers.
Ingenia Therapeutics is developing the "TIE-body" antibody platform, which directly activates TIE2, a vascular stabilization receptor, and the "LCIDEC" platform, which combines a function to remove disease-causing proteins, based on fundamental technologies from KAIST and IBS.
The lead pipeline retina disease new drug candidate "IGT-427" was transferred in 2022 to the U.K. ophthalmology-focused biotech EyeBio for more than 1 trillion won. Later, Merck acquired EyeBio for $3 billion, and development has continued under the name "MK-8748." A phase 3 trial is underway as a treatment for wet age-related macular degeneration, and a phase 3 trial for diabetic macular edema is also set to begin.
The company said it will accelerate development of subsequent pipelines. The chronic kidney disease treatment candidate "IGT-303" is in a phase 2a trial in Australia, New Zealand and Korea, with a goal of global technology transfer in 2027. It is also pushing to start clinical trials for the solid tumor treatment candidate "IGT-532."
Han Sang-yeol, CEO of Ingenia Therapeutics, said, "We have reached a major turning point through the KOSDAQ listing," and added, "We will focus on delivering results from subsequent pipelines to prove our technology in the global market and leap forward as corporations that grow together with shareholders."